(ZENA) ZenaTech - Overview
Stock: Cloud Software, Drones, Quantum Computing
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 140% |
| Relative Tail Risk | -23.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.12 |
| Alpha | -61.52 |
| Character TTM | |
|---|---|
| Beta | 1.758 |
| Beta Downside | 1.627 |
| Drawdowns 3y | |
|---|---|
| Max DD | 83.52% |
| CAGR/Max DD | -0.67 |
Description: ZENA ZenaTech January 17, 2026
ZenaTech Inc. (NASDAQ:ZENA) is a Vancouver-based enterprise software firm that builds cloud-based applications across several verticals, including electronic medical records, automated facility management, safety and compliance, field service, public-safety platforms, and emerging quantum-computing solutions. The company also manufactures, sells, and distributes drones, reflecting its legacy as ZenaDrone, Inc. (name change effective Oct 5 2020). Incorporated in 2017, ZenaTech operates primarily in Canada under the GICS sub-industry “Application Software.”
Key recent metrics (as of FY 2023) show annual revenue of roughly $12 million, up about 15 % year-over-year, with a SaaS recurring revenue run-rate near $8 million and a gross margin of 68 %. The Canadian enterprise-software market is projected to grow at a 12 % CAGR through 2027, driven by accelerated digital transformation in healthcare and public-sector agencies.
Sector drivers that could materially affect ZENA’s outlook include: (1) sustained government spending on digital health infrastructure, (2) increasing regulatory emphasis on safety-compliance software for critical facilities, and (3) the nascent but rapidly expanding quantum-computing services market, estimated at $2 billion globally in 2024.
For a deeper dive into ZENA’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-driven overview.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -26.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -11.41 > 1.0 |
| NWC/Revenue: 281.1% < 20% (prev 43.04%; Δ 238.1% < -1%) |
| CFO/TA -0.30 > 3% & CFO -23.3m > Net Income -26.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.6m) vs 12m ago 114.3% < -2% |
| Gross Margin: 27.62% > 18% (prev 0.98%; Δ 2665 % > 0.5%) |
| Asset Turnover: 16.70% > 50% (prev 9.07%; Δ 7.63% > 0%) |
| Interest Coverage Ratio: -1.71 > 6 (EBITDA TTM -20.4m / Interest Expense TTM 12.4m) |
Altman Z'' -4.27
| A: 0.30 (Total Current Assets 28.9m - Total Current Liabilities 5.34m) / Total Assets 78.6m |
| B: -0.40 (Retained Earnings -31.5m / Total Assets 78.6m) |
| C: -0.42 (EBIT TTM -21.2m / Avg Total Assets 50.3m) |
| D: -1.99 (Book Value of Equity -74.3m / Total Liabilities 37.3m) |
| Altman-Z'' Score: -4.27 = D |
Beneish M 1.00
| DSRI: 447.9 (Receivables 2.50m/1327 , Revenue 8.40m/1.99m) |
| GMI: 3.54 (GM 27.62% / 97.71%) |
| AQI: 0.62 (AQ_t 0.54 / AQ_t-1 0.88) |
| SGI: 4.21 (Revenue 8.40m / 1.99m) |
| TATA: -0.04 (NI -26.4m - CFO -23.3m) / TA 78.6m) |
| Beneish M-Score: 369.1 (Cap -4..+1) = D |
What is the price of ZENA shares?
Over the past week, the price has changed by -13.31%, over one month by -13.06%, over three months by -27.83% and over the past year by -40.81%.
Is ZENA a buy, sell or hold?
What are the forecasts/targets for the ZENA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.2 | 145.4% |
| Analysts Target Price | 7.2 | 145.4% |
| ValueRay Target Price | 2.9 | -2.7% |
ZENA Fundamental Data Overview February 05, 2026
P/E Trailing = 81.25
P/S = 18.4335
P/B = 7.9925
Revenue TTM = 8.40m CAD
EBIT TTM = -21.2m CAD
EBITDA TTM = -20.4m CAD
Long Term Debt = 31.3m CAD (from longTermDebt, last quarter)
Short Term Debt = 110.1k CAD (from shortTermDebt, last quarter)
Debt = 32.1m CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.9m CAD (from netDebt column, last quarter)
Enterprise Value = 224.1m CAD (211.5m + Debt 32.1m - CCE 19.5m)
Interest Coverage Ratio = -1.71 (Ebit TTM -21.2m / Interest Expense TTM 12.4m)
EV/FCF = -8.17x (Enterprise Value 224.1m / FCF TTM -27.4m)
FCF Yield = -12.24% (FCF TTM -27.4m / Enterprise Value 224.1m)
FCF Margin = -326.5% (FCF TTM -27.4m / Revenue TTM 8.40m)
Net Margin = -314.7% (Net Income TTM -26.4m / Revenue TTM 8.40m)
Gross Margin = 27.62% ((Revenue TTM 8.40m - Cost of Revenue TTM 6.08m) / Revenue TTM)
Gross Margin QoQ = -19.58% (prev 73.35%)
Tobins Q-Ratio = 2.85 (Enterprise Value 224.1m / Total Assets 78.6m)
Interest Expense / Debt = 22.66% (Interest Expense 7.28m / Debt 32.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -16.8m (EBIT -21.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.42 (Total Current Assets 28.9m / Total Current Liabilities 5.34m)
Debt / Equity = 0.78 (Debt 32.1m / totalStockholderEquity, last quarter 41.2m)
Debt / EBITDA = -1.07 (negative EBITDA) (Net Debt 21.9m / EBITDA -20.4m)
Debt / FCF = -0.80 (negative FCF - burning cash) (Net Debt 21.9m / FCF TTM -27.4m)
Total Stockholder Equity = 28.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.55% (Net Income -26.4m / Total Assets 78.6m)
RoE = -93.10% (Net Income TTM -26.4m / Total Stockholder Equity 28.4m)
RoCE = -35.58% (EBIT -21.2m / Capital Employed (Equity 28.4m + L.T.Debt 31.3m))
RoIC = 373.0% (negative operating profit) (NOPAT -16.8m / Invested Capital -4.50m)
WACC = 13.13% (E(211.5m)/V(243.6m) * Re(12.40%) + D(32.1m)/V(243.6m) * Rd(22.66%) * (1-Tc(0.21)))
Discount Rate = 12.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 47.34%
Fair Price DCF = unknown (Cash Flow -27.4m)
EPS Correlation: -95.29 | EPS CAGR: -97.36% | SUE: N/A | # QB: 0
Revenue Correlation: 38.27 | Revenue CAGR: 62.83% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=+0.020 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.23 | Chg30d=+0.270 | Revisions Net=-1 | Growth EPS=+72.0% | Growth Revenue=+140.3%